Clinical Trial Search

Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01

Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001

Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003

Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change

Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961

Primary: Total Dandruff Severity Score (TDSS) — 28.6; 29.3; 26.7; 2.1 units on a scale

Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants

Primary: Investigator Global Assessment (Scalp Only) — 1.59 score on a scale

Primary: The Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of "Clear" and "Almost Clear" With at Least 2-point Reduction From Baseline at Week…

Primary: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis — 41; 43 Participants — p=0.4557

Primary: Maintenance Phase: Time to First Relapse — 93.5; 56.8 days

Primary: Psoriasis Scalp Severity Index 90 (PSSI 90) — 52.9; 2.0 Percent of Participants — p=<0.001

Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001

Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…

Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Primary: Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 — 20 Participants

Primary: Achievement of Investigator Global Assessment (IGA) Success at Week 8 — 104; 27 Participants — p=<0.0001

Primary: Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if…

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Number of Participants With ≥1 Adverse Event (AE) — 17; 23; 90; 3 Participants

Primary: Clinical Response of Success — 6; 4; 6; 1 Participants — p=0.3571

Primary: Absolute Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Domain Total Score at Week 12 — 73.56; 72.07; 75.97 Score on a scale

Primary: Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16 — 48.5; 13.7; 50.0; 12.8 Percentage of responders…

Primary: Number of Participants With Any Adverse Event (AE) — 282 participants

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear…

Primary: SCORAD Change Score — 33.34 Change Score